참고문헌
- Abad A, Navarro M, Sastre J, et al (1997). A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group). Oncology, 11, 53-7.
- Adjani AA (2003). Pemetrexed (ALIMTAw): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther, 3, 145-55. https://doi.org/10.1586/14737140.3.2.145
- Adjei A (2004). Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res, 10, s4276-80. https://doi.org/10.1158/1078-0432.CCR-040010
- Atkins JN, Jacobs SA, Wieand HS, et al (2005). Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clin Colorectal Cancer, 5, 181-7. https://doi.org/10.3816/CCC.2005.n.029
- Chen Q, Xia HW, Ge XJ, et al (2013). Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev, 14, 7421-6. https://doi.org/10.7314/APJCP.2013.14.12.7421
- Cripps C, Burnell M, Jolivet J, et al (1999). Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol, 10, 1175-9. https://doi.org/10.1023/A:1008372529239
- Grem JL. Fluorinated pyrimidines (1990). In Chabner BA, Collins JM (eds): Cancer Chemotherapy: Principles and Practice. Philadelphia, PA: Lippincott, 180-24.
- Grindey GB, Shih C, Barnett CJ et al (1992). LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res, 33, 411 (Abstr).
- Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001). Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist, 6, 363-73. https://doi.org/10.1634/theoncologist.6-4-363
-
Hazarika M, White RM, Johnson JR, et al (2004). FDA drug approval summaries: pemetrexed (Alimta
$^{(R)}$ ). Oncologist, 9, 482-8. https://doi.org/10.1634/theoncologist.9-5-482 - Hochster H, Kettner E, Kroning H, et al (2005). Phase I/II doseescalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. Clin Colorectal Cancer, 5, 257-62. https://doi.org/10.3816/CCC.2005.n.036
- Hu XQ, Yuan P, Luan RS, et al (2013). Calpain-10 SNP43 and SNP19 polymorphisms and colorectal cancer: a matched case-control study. Asian Pac J Cancer Prev, 14, 6673-80 https://doi.org/10.7314/APJCP.2013.14.11.6673
- John W, Picus J, Blanke CD, et al (2000). Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer, 8, 1807-13.
- Louvet C (2004), Pemetrexed in advanced colorectal cancer. Oncology, 18, 56-62.
- Louvet C1, Andre T, Gamelin E, et al (2010). Phase II study of biweekly pemetrexed plus irinotecan as second-line therapy for metastatic colorectal cancer. J Oncol, 2010, 785934.
- Mendelsohn LG, Shih C, Chen VJ et al (1999). Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol, 26, 42-7.
- Niyikiza C, Baker SD, Seitz DE, et al (2002). Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther, 1, 545-552.
- Pandurangan AK, Ananda Sadagopan SK, Dharmalingam P, et al (2013). Luteolin, a bioflavonoid, attenuates azoxymethaneinduced effects on mitochondrial enzymes in BALB/c mice. Asian Pac J Cancer Prev, 14, 6669-72. https://doi.org/10.7314/APJCP.2013.14.11.6669
- Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43 https://doi.org/10.1016/S1470-2045(01)00486-7
- Renaldo DA, Burris HA, Dorr FA et al (1995). Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol, 13, 2842-50.
- Ronald DA, Kuhn JG, Burris HA et al (1999). A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol, 44, 372-80. https://doi.org/10.1007/s002800050992
- Rowinsky EK, Beeram M, Hammond LA, et al (2007). A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. Clin Cancer Res, 13, 532-9. https://doi.org/10.1158/1078-0432.CCR-06-1606
- Schilsky RL (1992). Antimetabolites. In Perry MC (ed.): The Chemotherapy Source Book. Baltimore, MD: Williams and Wilkins, 301-15.
- Shih C, Chen VC, Gossett LS et al (1997). LY231514, a pyrrolo (2, 3-d) pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res, 57, 1116-23.
- Shih C, Grindey GB, Barnett CJ et al (1992). Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514. Proc Am Assoc Cancer Res, 33, 411 (Abstr).
- Shih C, Thornton DE (1999). Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514).
- In Jackman AL (ed.): Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press, Inc, 183-01.
- Simsek EN, Uysal T (2013). In vitro investigation of cytotoxic and apoptotic effects of Cynara L. species in colorectal cancer cells. Asian Pac J Cancer Prev, 14, 6791-5. https://doi.org/10.7314/APJCP.2013.14.11.6791
- Sung JJ, Lau JY, Goh KL, et a1 (2005). Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncel, 6, 871-6. https://doi.org/10.1016/S1470-2045(05)70422-8
- Underhill C1, Goldstein D, Gorbounova VA, et al (2007). A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. Oncology, 73, 9-20. https://doi.org/10.1159/000120626
-
Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar
$^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90. - Yu M, Niu ZM, Wei YQ (2013). Effective response of the peritoneum microenvironment to peritoneal and systemic metastasis from colorectal carcinoma. Asian Pac J Cancer Prev, 14, 7289-94. https://doi.org/10.7314/APJCP.2013.14.12.7289
피인용 문헌
- Types of Cancers Prevailing in Pakistan and their Management Evaluation vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3605